Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Cui, Wenli ^a,b,c   Cai, Ying ^a,b   Wang, Weige ^a,b   Liu, Zebing ^a,b   Wei, Ping ^a,b   Bi, Rui ^a,b   Chen, Weixiang ^a,b   Sun, Menghong ^a,b   Zhou, Xiaoyan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

CNV; DLBCL; PI3K AKT; Subunits; Survival

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110ALPHA; PROTEIN P110BETA; PROTEIN P110DELTA; PROTEIN P110GAMMA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AKT GENE; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE ACTIVATION; GENE LOSS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; P110ALPHA GENE; P110BETA GENE; P110DELTA GENE; P110GAMMA GENE; PIK3CA GENE; PIK3CB GENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR GENE;

DNA COPY NUMBER VARIATIONS; GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84892389955     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-10     Document Type: Article

References (27)

1. Swerdlow SH, Campo E, Harri ES, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, Lyon: IARC.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
3. Beer-Hammer S, Zebedin E, von Holleben M, Alferink J, Reis B, Dresing P, Degrandi D, Scheu S, Hirsch E, Sexl V, et al. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J Leukoc Biol 2010, 87:1083-1095. 10.1189/jlb.0809585, 20200404.
4. Engelman JA, Luo J. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Gen 2006, 7:606-619.
5. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, Atizado V, Al-Dayel F, Belgaumi A, El-Solh H, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186. 10.1182/blood-2006-04-016907, 16946303.
6. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779. 2750091, 18594509.
7. Agell L, Hernandez S, Salido M, de Muga S, Juanpere N, Arumi-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod Pathol 2011, 24:443-452. 10.1038/modpathol.2010.208, 21113138.
8. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, Argyriou P, Pectasides D, Harhalakis N, Pappa V, et al. Phosphatidylinositol 3′-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009, 15:5724-5732. 10.1158/1078-0432.CCR-08-3215, 19723646.
9. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012, 18:3791-3802. 10.1158/1078-0432.CCR-11-2342, 3719990, 22623730.
10. Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 2008, 17:159-165. 10.1097/PDM.0b013e31815d0588, 18382359.
11. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013, 110:1398-1403. 10.1073/pnas.1205299110, 3557051, 23292937.
12. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282. 10.1182/blood-2003-05-1545, 14504078.
13. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008, 26:317-325. 10.1038/nbt1385, 18278033.
14. Zhang L, Huang J, Yang N, Greshock J, Liang S, Hasegawa K, Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D, et al. Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007, 13:5314-5321. 10.1158/1078-0432.CCR-06-2660, 17875760.
15. Grabinski N, Bartkowiak K, Grupp K, Brandt B, Pantel K, Jucker M. Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal 2011, 23:1952-1960. 10.1016/j.cellsig.2011.07.003, 21777670.
16. Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, et al. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One 2012, 7:e30427. 10.1371/journal.pone.0030427, 3281846, 22363436.
17. Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, et al. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011, 50:606-618. 10.1002/gcc.20883, 3110626, 21563232.
18. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY. PIK3CA as an oncogene in cervical cancer. Oncogene 2000, 19:2739-2744. 10.1038/sj.onc.1203597, 10851074.
19. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012, 12:50. 10.1186/1471-2407-12-50, 3299648, 22292935.
20. Kreisel F, Kulkarni S, Kerns RT, Hassan A, Deshmukh H, Nagarajan R, Frater JL, Cashen A. High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy. Cancer Genet 2011, 204:129-137. 10.1016/j.cancergen.2010.12.010, 3837631, 21504712.
21. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511. 10.1038/35000501, 10676951.
22. Ye ZQ, Niu S, Yu Y, Yu H, Liu BH, Li RX, Xiao HS, Zeng R, Li YX, Wu JR, Li YY. Analyses of copy number variation of GK rat reveal new putative type 2 diabetes susceptibility loci. PLoS One 2010, 5:e14077. 10.1371/journal.pone.0014077, 2990713, 21124896.
23. Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012, 119:1897-1900. 10.1182/blood-2011-10-386763, 22210877.
24. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 2011, 127:407-416. 10.1007/s10549-010-1012-y, 20617378.
25. Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM, Lugli A. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol 2011, 42:1888-1896. 10.1016/j.humpath.2010.06.020, 21664646.
26. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, Yamashita Y, Kanemura M, Ueda M, Sugita M, et al. Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 2011, 11:50-57. 10.4161/cbt.11.1.13877, 3047101, 21057220.
27. Hasselblom S, Hansson U, Olsson M, Toren L, Bergstrom A, Nilsson-Ehle H, Andersson PO. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010, 149:560-568. 10.1111/j.1365-2141.2010.08123.x, 20201946.